Table of Contents Author Guidelines Submit a Manuscript
Experimental Diabetes Research
Volume 2011, Article ID 162092, 12 pages
http://dx.doi.org/10.1155/2011/162092
Research Article

Diabetic Nephropathy Amelioration by a Low-Dose Sitagliptin in an Animal Model of Type 2 Diabetes (Zucker Diabetic Fatty Rat)

1Laboratory of Pharmacology & Experimental Therapeutics, Institute for Biomedical Research on Light and Image (IBILI), Medicine Faculty, Coimbra University, 3000-548 Coimbra, Portugal
2Agrarian School of Viseu, Polytechnic Institute of Viseu, 3500-606 Viseu, Portugal
3Educational, Technologies and Health Study Center, Polytechnic Institute of Viseu, 3504-510 Viseu, Portugal

Received 1 July 2011; Revised 21 August 2011; Accepted 29 August 2011

Academic Editor: Yoshio Shimizu

Copyright © 2011 Cristina Mega et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. S. Wild, G. Roglic, A. Green, R. Sicree, and H. King, “Global prevalence of diabetes: estimates for the year 2000 and projections for 2030,” Diabetes Care, vol. 27, no. 5, pp. 1047–1053, 2004. View at Publisher · View at Google Scholar · View at Scopus
  2. R. A. Defronzo, “From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus,” Diabetes, vol. 58, no. 4, pp. 773–795, 2009. View at Publisher · View at Google Scholar · View at Scopus
  3. S. P. Gray and M. E. Cooper, “Diabetic nephropathy in 2010: alleviating the burden of diabetic nephropathy,” Nature Reviews Nephrology, vol. 7, no. 2, pp. 71–73, 2011. View at Publisher · View at Google Scholar
  4. K. Marchant, “Diabetes and chronic kidney disease: a complex combination,” British Journal of Nursing, vol. 17, no. 6, pp. 356–361, 2008. View at Google Scholar · View at Scopus
  5. M. H. Crawford, “Diabetes, the kidney, and cardiovascular risk. Foreword,” Cardiology Clinics, vol. 28, no. 3, p. 9, 2010. View at Google Scholar · View at Scopus
  6. J. H. Stewart, M. R. E. McCredie, S. M. Williams, K. J. Jager, L. Trpeski, and S. P. McDonald, “Trends in incidence of treated end-stage renal disease, overall and by primary renal disease, in persons aged 20-64 years in Europe, Canada and the Asia-Pacific region, 1998-2002,” Nephrology, vol. 12, no. 5, pp. 520–527, 2007. View at Publisher · View at Google Scholar
  7. K. Wakai, S. Nakai, K. Kikuchi et al., “Trends in incidence of end-stage renal disease in Japan, 1983-2000: age-adjusted and age-specific rates by gender and cause,” Nephrology Dialysis Transplantation, vol. 19, no. 8, pp. 2044–2052, 2004. View at Publisher · View at Google Scholar · View at Scopus
  8. C. Lorenzo, S. D. Nath, A. J. G. Hanley, H. E. Abboud, and S. M. Haffner, “Relation of low glomerular filtration rate to metabolic disorders in individuals without diabetes and with normoalbuminuria,” Clinical Journal of the American Society of Nephrology, vol. 3, no. 3, pp. 783–789, 2008. View at Publisher · View at Google Scholar · View at Scopus
  9. W. T. Noonan, V. M. Shapiro, and R. O. Banks, “Renal glucose reabsorption during hypertonic glucose infusion in female streptozotocin-induced diabetic rats,” Life Sciences, vol. 68, no. 26, pp. 2967–2977, 2001. View at Publisher · View at Google Scholar · View at Scopus
  10. J. H. Dominguez, K. Camp, L. Maianu, H. Feister, and W. T. Garvey, “Molecular adaptations of GLUT1 and GLUT2 in renal proximal tubules of diabetic rats,” American Journal of Physiology, vol. 266, no. 2, pp. F283–F290, 1994. View at Google Scholar · View at Scopus
  11. M. Kamran, R. G. Peterson, and J. H. Dominguez, “Overexpression of GLUT2 gene in renal proximal tubules of diabetic Zucker rats,” Journal of the American Society of Nephrology, vol. 8, no. 6, pp. 943–948, 1997. View at Google Scholar · View at Scopus
  12. P. Balakumar, M. K. Arora, J. Reddy, and M. B. Anand-Srivastava, “Pathophysiology of diabetic nephropathy: involvement of multifaceted signalling mechanism,” Journal of Cardiovascular Pharmacology, vol. 54, no. 2, pp. 129–138, 2009. View at Publisher · View at Google Scholar · View at Scopus
  13. S. Sego, “Pathophysiology of diabetic nephropathy,” Nephrology Nursing Journal, vol. 34, no. 6, pp. 631–633, 2007. View at Google Scholar · View at Scopus
  14. D. K. Singh, P. Winocour, and K. Farrington, “Oxidative stress in early diabetic nephropathy: fueling the fire,” Nature Reviews Endocrinology, vol. 7, no. 3, pp. 176–184, 2011. View at Publisher · View at Google Scholar · View at Scopus
  15. A. Rivero, C. Mora, M. Muros, J. García, H. Herrera, and J. F. Navarro-González, “Pathogenic perspectives for the role of inflammation in diabetic nephropathy,” Clinical Science, vol. 116, no. 6, pp. 479–492, 2009. View at Publisher · View at Google Scholar · View at Scopus
  16. T. Chawla, D. Sharma, and A. Singh, “Role of the renin angiotensin system in diabetic nephropathy,” World Journal of Diabetes, vol. 1, no. 5, pp. 141–145, 2010. View at Google Scholar
  17. S. Morano, R. Cipriani, C. Santangelo et al., “Angiotensin blockade and matrix synthesis by glomerular epithelial cells in high glucose: a further experimental insight into the pathophysiology of diabetic nephropathy,” Clinica Terapeutica, vol. 159, no. 3, pp. 151–154, 2008. View at Google Scholar · View at Scopus
  18. T. Bouattar, S. Ahid, S. Benasila et al., “The factors for progression of the diabetic nephropathy: management and evolution,” Nephrologie et Therapeutique, vol. 5, no. 3, pp. 181–187, 2009. View at Publisher · View at Google Scholar · View at Scopus
  19. R. Bilous, “The prevalence and management of cardiorenal risk factors in patients with diabetic nephropathy,” Nature Clinical Practice Endocrinology and Metabolism, vol. 2, no. 10, pp. 548–549, 2006. View at Publisher · View at Google Scholar
  20. A. J. Krentz, G. Clough, and C. D. Byrne, “Vascular disease in the metabolic syndrome: do we need to target the microcirculation to treat large vessel disease?” Journal of Vascular Research, vol. 46, no. 6, pp. 515–526, 2009. View at Publisher · View at Google Scholar · View at Scopus
  21. C. S. Mizuno, A. G. Chittiboyina, T. W. Kurtz, H. A. Pershadsingh, and M. A. Avery, “Type 2 diabetes and oral antihyperglycemic drugs,” Current Medicinal Chemistry, vol. 15, no. 1, pp. 61–74, 2008. View at Publisher · View at Google Scholar · View at Scopus
  22. J. P. Frias and S. V. Edelman, “Incretins and their role in the management of diabetes,” Current Opinion in Endocrinology, vol. 14, no. 4, pp. 269–276, 2007. View at Publisher · View at Google Scholar · View at Scopus
  23. B. T. Srinivasan, J. Jarvis, K. Khunti, and M. J. Davies, “Recent advances in the management of type 2 diabetes mellitus: a review,” Postgraduate Medical Journal, vol. 84, no. 996, pp. 524–531, 2008. View at Publisher · View at Google Scholar · View at Scopus
  24. J. Girard, “The incretins: from the concept to their use in the treatment of type2 diabetes. Part A: incretins: concept and physiological functions,” Diabetes and Metabolism, vol. 34, no. 6, pp. 550–559, 2008. View at Publisher · View at Google Scholar · View at Scopus
  25. J. F. Gautier, S. P. Choukem, and J. Girard, “Physiology of incretins (GIP and GLP-1) and abnormalities in type 2 diabetes,” Diabetes and Metabolism, vol. 34, supplement 2, pp. S65–S72, 2008. View at Publisher · View at Google Scholar · View at Scopus
  26. J. Unger, “Incretins: clinical perspectives, relevance, and applications for the primary care physician in the treatment of patients with type 2 diabetes mellitus,” Mayo Clinic Proceedings, vol. 85, supplement 12, pp. S38–S49, 2010. View at Publisher · View at Google Scholar · View at Scopus
  27. T. Ábel and J. Fehér, “A new therapeutic class for the therapy of type 2 diabetes: DPP-4 inhibitors (sitagliptin),” Orvosi Hetilap, vol. 151, no. 25, pp. 1012–1016, 2010. View at Publisher · View at Google Scholar · View at Scopus
  28. S. Dhillon, “Sitagliptin: a review of its use in the management of type 2 diabetes mellitus,” Drugs, vol. 70, no. 4, pp. 489–512, 2010. View at Publisher · View at Google Scholar · View at Scopus
  29. R. G. Peterson, W. N. Shaw, M. A. Neel, L. A. Little, and J. Eichberg, “Zucker diabetic fatty rat as a model for non-insulin dependent diabetes mellitus,” Institute for Laboratory Animal Research Journal, vol. 32, pp. 16–19, 1990. View at Google Scholar
  30. U. Janssen, A. O. Phillips, and J. Floege, “Rodent models of nephropathy associated with type II diabetes,” Journal of Nephrology, vol. 12, no. 3, pp. 159–172, 1999. View at Google Scholar · View at Scopus
  31. A. O. Phillips, U. Janssen, and J. Floege, “Progression of diabetic nephropathy. Insights from cell culture studies and animal models,” Kidney and Blood Pressure Research, vol. 22, no. 1-2, pp. 81–97, 1999. View at Publisher · View at Google Scholar · View at Scopus
  32. L. Ferreira, E. Teixeira-De-Lemos, F. Pinto et al., “Effects of sitagliptin treatment on dysmetabolism, inflammation, and oxidative stress in an animal model of type 2 diabetes (ZDF rat),” Mediators of Inflammation, vol. 2010, Article ID 592760, 2010. View at Publisher · View at Google Scholar · View at Scopus
  33. D. J. Drucker, “The biology of incretin hormones,” Cell Metabolism, vol. 3, no. 3, pp. 153–165, 2006. View at Publisher · View at Google Scholar · View at Scopus
  34. J. J. Holst, T. Vilsbøll, and C. F. Deacon, “The incretin system and its role in type 2 diabetes mellitus,” Molecular and Cellular Endocrinology, vol. 297, no. 1-2, pp. 127–136, 2009. View at Publisher · View at Google Scholar · View at Scopus
  35. T. M. Wallace, J. C. Levy, and D. R. Matthews, “Use and abuse of HOMA modeling,” Diabetes Care, vol. 27, no. 6, pp. 1487–1495, 2004. View at Publisher · View at Google Scholar · View at Scopus
  36. S. Hoshi, Y. Shu, F. Yoshida et al., “Podocyte injury promotes progressive nephropathy in zucker diabetic fatty rats,” Laboratory Investigation, vol. 82, no. 1, pp. 25–35, 2002. View at Google Scholar · View at Scopus
  37. T. W. C. Tervaert, A. L. Mooyaart, K. Amann et al., “Pathologic classification of diabetic nephropathy,” Journal of the American Society of Nephrology, vol. 21, no. 4, pp. 556–563, 2010. View at Publisher · View at Google Scholar · View at Scopus
  38. B. Sudre, P. Broqua, R. B. White et al., “Chronic inhibition of circulating dipeptidyl peptidase IV by FE 999011 delays the occurrence of diabetes in male Zucker diabetic fatty rats,” Diabetes, vol. 51, no. 5, pp. 1461–1469, 2002. View at Google Scholar · View at Scopus
  39. J. A. Pospisilik, S. G. Stafford, H. U. Demuth, C. H. S. McIntosh, and R. A. Pederson, “Long-term treatment with dipeptidyl peptidase IV inhibitor improves hepatic and peripheral insulin sensitivity in the VDF Zucker rat: a euglycemic-hyperinsulinemic clamp study,” Diabetes, vol. 51, no. 9, pp. 2677–2683, 2002. View at Google Scholar · View at Scopus
  40. M. G. Beconi, J. R. Reed, Y. Teffera et al., “Disposition of the dipeptidyl peptidase 4 inhibitor sitagliptin in rats and dogs,” Drug Metabolism and Disposition, vol. 35, no. 4, pp. 525–532, 2007. View at Publisher · View at Google Scholar · View at Scopus
  41. N. Kambham, G. S. Markowitz, A. M. Valeri, J. Lin, and V. D. D'Agati, “Obesity-related glomerulopathy: an emerging epidemic,” Kidney International, vol. 59, no. 4, pp. 1498–1509, 2001. View at Publisher · View at Google Scholar · View at Scopus
  42. S. Kato, A. Nazneen, Y. Nakashima et al., “Pathological influence of obesity on renal structural changes in chronic kidney disease,” Clinical and Experimental Nephrology, vol. 13, no. 4, pp. 332–340, 2009. View at Publisher · View at Google Scholar · View at Scopus
  43. N. Gassler, M. Elger, B. Kränzlin et al., “Podocyte injury underlies the progression of focal segmental glomerulosclerosis in the fa/fa Zucker rat,” Kidney International, vol. 60, no. 1, pp. 106–116, 2001. View at Publisher · View at Google Scholar · View at Scopus
  44. J. P. Vora, S. M. Zimsen, D. C. Houghton, and S. Anderson, “Evolution of metabolic and renal changes in the ZDF/Drt-fa rat model of type II diabetes,” Journal of the American Society of Nephrology, vol. 7, no. 1, pp. 113–117, 1996. View at Google Scholar · View at Scopus
  45. P. Janiak, J. P. Bidouard, C. Cadrouvele et al., “Long-term blockade of angiotensin AT1 receptors increases survival of obese Zucker rats,” European Journal of Pharmacology, vol. 534, no. 1–3, pp. 271–279, 2006. View at Publisher · View at Google Scholar · View at Scopus
  46. S. Schäfer, H. L. Schmidts, M. Bleich, A. E. Busch, and W. Linz, “Nephroprotection in Zucker diabetic fatty rats by vasopeptidase inhibition is partly bradykinin B2 receptor dependent,” British Journal of Pharmacology, vol. 143, no. 1, pp. 27–32, 2004. View at Publisher · View at Google Scholar · View at Scopus
  47. B. F. Schrijvers, A. Flyvbjerg, R. G. Tilton, N. H. Lameire, and A. S. De Vriese, “A neutralizing VEGF antibody prevents glomerular hypertrophy in a model of obese type 2 diabetes, the Zucker diabetic fatty rat,” Nephrology Dialysis Transplantation, vol. 21, no. 2, pp. 324–329, 2006. View at Publisher · View at Google Scholar · View at Scopus
  48. J. Mu, J. Woods, Y. P. Zhou et al., “Chronic inhibition of dipeptidyl peptidase-4 with a sitagliptin analog preserves pancreatic β-cell mass and function in a rodent model of type 2 diabetes,” Diabetes, vol. 55, no. 6, pp. 1695–1704, 2006. View at Publisher · View at Google Scholar · View at Scopus
  49. T. Matsui, Y. Nishino, M. Takeuchi, and S.-I. Yamagishi, “Vildagliptin blocks vascular injury in thoracic aorta of diabetic rats by suppressing advanced glycation end product-receptor axis,” Pharmacological Research, vol. 63, no. 5, pp. 383–388, 2011. View at Publisher · View at Google Scholar
  50. L. Li, W. El-Kholy, C. J. Rhodes, and P. L. Brubaker, “Glucagon-like peptide-1 protects beta cells from cytokine-induced apoptosis and necrosis: role of protein kinase B,” Diabetologia, vol. 48, no. 7, pp. 1339–1349, 2005. View at Publisher · View at Google Scholar · View at Scopus
  51. X. Zhang, Z. Wang, Y. Huang, and J. Wang, “Effects of chronic administration of alogliptin on the development of diabetes and β-cell function in high fat diet/streptozotocin diabetic mice,” Diabetes, Obesity and Metabolism, vol. 13, no. 4, pp. 337–347, 2011. View at Publisher · View at Google Scholar
  52. J. M. Chang, M. C. Kuo, H. T. Kuo, Y. W. Chiu, and H. C. Chen, “Increased glomerular and extracellular malondialdehyde levels in patients and rats with diabetic nephropathy,” Journal of Laboratory and Clinical Medicine, vol. 146, no. 4, pp. 210–215, 2005. View at Publisher · View at Google Scholar · View at Scopus
  53. J. Vaghasiya, N. Sheth, Y. Bhalodia, and R. Manek, “Sitagliptin protects renal ischemia reperfusion induced renal damage in diabetes,” Regulatory Peptides, vol. 166, no. 1–3, pp. 48–54, 2011. View at Publisher · View at Google Scholar · View at Scopus
  54. R. F. Rosario and S. Prabhakar, “Lipids and diabetic nephropathy,” Current Diabetes Reports, vol. 6, no. 6, pp. 455–462, 2006. View at Publisher · View at Google Scholar · View at Scopus
  55. M. Lassila, K. K. Seah, T. J. Allen et al., “Accelerated nephropathy in diabetic apolipoprotein E-knockout mouse: role of advanced glycation end products,” Journal of the American Society of Nephrology, vol. 15, no. 8, pp. 2125–2138, 2004. View at Publisher · View at Google Scholar · View at Scopus
  56. J. H. Dominguez, N. Tang, W. Xu et al., “Studies of renal injury III: lipid-induced nephropathy in type II diabetes,” Kidney International, vol. 57, no. 1, pp. 92–104, 2000. View at Publisher · View at Google Scholar · View at Scopus
  57. P. N. Chander, O. Gealekman, S. V. Brodsky et al., “Nephropathy in Zucker diabetic fat rat is associated with oxidative and nitrosative stress: prevention by chronic therapy with a peroxynitrite scavenger ebselen,” Journal of the American Society of Nephrology, vol. 15, no. 9, pp. 2391–2403, 2004. View at Publisher · View at Google Scholar · View at Scopus
  58. Y. Suzaki, Y. Ozawa, and H. Kobori, “Intrarenal oxidative stress and augmented angiotensinogen are precedent to renal injury in zucker diabetic fatty rats,” International Journal of Biological Sciences, vol. 3, no. 1, pp. 40–46, 2006. View at Google Scholar · View at Scopus
  59. A. C. C. Girardi, L. E. Fukuda, L. V. Rossoni, G. Malnic, and N. A. Rebouças, “Dipeptidyl peptidase IV inhibition downregulates Na+-H + exchanger NHE3 in rat renal proximal tubule,” American Journal of Physiology, vol. 294, no. 2, pp. F414–F422, 2008. View at Publisher · View at Google Scholar · View at Scopus
  60. Y. Ishibashi, Y. Nishino, T. Matsui, M. Takeuchi, and S.-I. Yamagishi, “Glucagon-like peptide-1 suppresses advanced glycation end product-induced monocyte chemoattractant protein-1 expression in mesangial cells by reducing advanced glycation end product receptor level,” Metabolism, vol. 60, no. 9, pp. 1271–1277, 2011. View at Publisher · View at Google Scholar